Use of canakinumab and remdesivir in moderate-severe COVID-19 patients: A retrospective analysis
International Journal of Immunopathology and Pharmacology · 2023
DOI: 10.1177/03946320231189993 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift International Journal of Immunopathology and Pharmacology, 2023. Verfasst von Antonio Mastroianni und 8 weiteren Autor:innen. Beteiligte Einrichtung: Infectious & Tropical Diseases Unit, "Annunziata" Hospital, Azienda Ospedaliera di Cosenza, Cosenza, Italy. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Objectives
The dysregulated immune response occurring upon COVID-19 infection can lead to tissue damage and organ failure. Different therapeutic strategies are needed to cope with the current and future outspread of COVID-19, including antiviral and anti-inflammatory agents. We describe the outcome of hospitalized patients treated with canakinumab and remdesivir plus the standard of care therapy.
Methods
This observational study describes the outcome of the combination of canakinumab (450 mg for patients ≥40 and
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Infectious & Tropical Diseases Unit, "Annunziata" Hospital, Azienda Ospedaliera di Cosenza, Cosenza, Italy.
- Hospital Pharmacy, "Annunziata" Hospital, Azienda Ospedaliera di Cosenza, Cosenza, Italy.
- Radiology Unit, "Annunziata" Hospital, Azienda Ospedaliera di Cosenza, Cosenza, Italy.
- Microbiology & Virology Unit, "Annunziata" Hospital, Azienda Ospedaliera di Cosenza, Cosenza, Italy.
ORCID-Profile: Antonio Mastroianni
Zitieren
APA
Mastroianni, A., Vangeli, V., Chidichimo, L., Urso, F., De Marco, G., Zanolini, A., Greco, F., Mauro, M. V., & Greco, S. (2023). Use of canakinumab and remdesivir in moderate-severe COVID-19 patients: A retrospective analysis. International Journal of Immunopathology and Pharmacology. https://doi.org/10.1177/03946320231189993
Vancouver
Mastroianni A, Vangeli V, Chidichimo L, Urso F, De Marco G, Zanolini A, et al. Use of canakinumab and remdesivir in moderate-severe COVID-19 patients: A retrospective analysis. International Journal of Immunopathology and Pharmacology. 2023. doi:10.1177/03946320231189993
BibTeX
@article{Mastroianni2023,
author = {Mastroianni, Antonio and Vangeli, Valeria and Chidichimo, Luciana and Urso, Filippo and De Marco, Giuseppe and Zanolini, Alfredo and Greco, Francesca and Mauro, Maria V and Greco, Sonia},
title = {Use of canakinumab and remdesivir in moderate-severe COVID-19 patients: A retrospective analysis},
journal = {International Journal of Immunopathology and Pharmacology},
year = {2023},
doi = {10.1177/03946320231189993}
}
EUVIMED